Pakistan Launches Advanced Local Therapies for Diabetes and Obesity Care
Oct 24, 2025
Pakistan’s healthcare system has entered a transformative phase in diabetes and obesity management, as locally manufactured advanced GLP-1 and GIP receptor agonist (RA) therapies become available for patients nationwide.
For years, these innovative incretin-based medicines—renowned globally for controlling blood sugar and supporting healthy weight loss—were accessible only through expensive imports. Now, with local production underway, patients can expect affordable and reliable access to world-class treatment options.
What Makes These Treatments Special
GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide) RAs mimic the body’s natural hormones that regulate insulin, appetite, and digestion. They help manage blood sugar levels, promote satiety, and support sustainable weight reduction. Studies have also linked these therapies to improved heart and liver health, making them a cornerstone of modern metabolic medicine.
A Global Trend, Now Available Locally
Drugs like semaglutide and tirzepatide have revolutionized treatment abroad—and now, Pakistan joins the list of countries making them locally accessible. Several pharmaceutical companies have started producing biosimilar versions that meet international quality and safety standards, ensuring the same clinical benefits at a lower cost.
Local Manufacturing: A Milestone for Affordability
Imported versions of these therapies once cost five to ten times the average monthly household income. Local manufacturing is set to reduce prices, stabilize supply, and expand patient access.
Professor Dr. Javed Akram, a leading medical expert, praised this development, saying:
“These medicines have long been life-changing, but affordability was the biggest barrier. Now, with world-class local production, patients finally have access to effective and safe treatment options.”
Among the pioneers, Getz Pharma has become the first company in the world to produce all three advanced GLP-1 and GIP RA therapies locally:
-
Tirzepatide injection (Tirzee) — a once-weekly dual-acting therapy with a convenient auto-injector.
-
Semaglutide injection (SEM-P) — available in vial and pre-filled pen formats for flexible dosing.
-
Oral semaglutide (SEM-O) — the first peptide-based tablet that eliminates the need for injections.
Supporting Patients Through Education
Experts emphasize that these prescription-only treatments should be paired with nutrition, exercise, and professional medical supervision to ensure safe and effective outcomes. Ongoing education and lifestyle support remain key components of successful diabetes and obesity management.
Toward a Healthier, More Equitable Future
The local availability of GLP-1 and GIP RA therapies marks a major leap toward affordable, high-quality metabolic care in Pakistan. As awareness grows and costs decline, this initiative could make Pakistan a regional leader in accessible healthcare innovation—bridging the gap between global science and local needs.
